The Baker brothers are billionaires with a successful track record in the biopharmaceutical industry.
The pharma's latest push to develop a weight loss pill isn't going well.
/CNW/ -- Merchant Law Group LLP and Pfizer Inc., Pfizer Canada Inc., Pfizer Canada Inc.'s successor Pfizer Canada ULC, Wyeth, Wyeth Canada, Wyeth Canada Inc.,...
Despite their recent underperformance, these two phenomenal dividend stocks -- sporting an average yield of 5.79% -- have the recipes to make their patient shareholders notably richer.
Medical Properties Trust's yield looks appealing, but it wouldn't have made up for the stock's 70% decline over the last three years.
/Pfizer%20Inc_%20logo%20on%20iPad-by%20Koshiro%20K%20via%20Shutterstock.jpg)
As Pfizer gears up to release its second-quarter earnings this month, analysts project a double-digit bottom-line dip.
Pfizer's stock presents a compelling investment opportunity, trading at an attractive valuation with a high dividend yield, as the company makes promising progress on its oral obesity drug, danuglipron,...
This week we have Taiwan Semiconductor (TSM), Bank of America (BAC), United Airlines (UAL), Netflix (NFLX), Goldman Sachs (GS), Johnson & Johnson (JNJ) and Morgan Stanley (MS) all set to report.
These drugmakers may not be in perfect health right now, but that shouldn't last much longer.
The S&P 500 Index ($SPX ) (SPY ) today is down -0.56%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.21%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -1.21%. Stock indexes today are mixed,...